Mechanisms modifying atherosclerotic disease - From lipids to vascular biology

Atherosclerosis

Volumn 147, Issue SUPPL. 1, 1999, Pages

  Weissberg, Peter ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Fibrous cap; Inflammation; Plaque stability; Smooth muscle cells; Statins

Indexed keywords

ATORVASTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RUPTURE; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOGENESIS; THROMBUS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; THROMBOSIS;

EID: 0032865010     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00249-X     Document Type: Conference Paper

References (63)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340(2):1999;115-126.
2. Davies M.J. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture. Circulation. 94:1996;2013-2020.
3. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
4. Treasure C.B., Klein J.L., Weintraub W.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332(8):1995;481-487.
5. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 31:1998;684-691.
6. Lacoste L., Lam J.Y.T., Hung J. et al. Hyperlipidaemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 92:1995;3172-3177.
7. Negre-Aminoux P., van Vliet A.K., van Erck M. et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim. Biophys. Acta. 1345:1997;259-268.
8. Ridker P.M., Rifai N., Pfeffer M.A. et al. for the CARE Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
9. Stary J.C., Chandler A.B., Glagov S. et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council of Arteriosclerosis, American Heart Association. Circulation. 89:1994;2462-2478.
10. Clarkson P., Celermajer D.S., Powe A.J. et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 96:1997;3378-3383.
11. Nakashima Y., Raines E.W., Plump A.S. et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apo-E-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18:1998;842-851.
12. Hynes R.O., Wagner D.D. Genetic manipulation of vascular adhesion molecules in mice. J. Clin. Invest. 98:1996;2193-2195.
13. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:1997;20963-20966.
14. Rajahvashisth T.B., Andalibi A., Territo M.C. et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature. 344:1990;254-257.
15. Shanahan C.M., Weissberg P.L. Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 18:1998;333-338.
16. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
17. Cheng G.C., Loree H.M., Kamm R.D. et al. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structured analysis with histopathological correlation. Circulation. 87:1993;1179-1187.
18. Bennett M.R., Macdonald K., Chan S.-W. et al. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ. Res. 82:1998;704-712.
19. Bennett M.R., Boyle J.J. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 138:1998;3-9.
20. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
21. Galis Z., Sukhova G., Lark M., Libby P. Increased expression of matrix metalloproteinases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:1994;2493-2503.
22. Amento E.P., Ehsani N., Palmer H., Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Atherioscler. Thromb. 11:1991;1223-1230.
23. Hansson G.K., Libby P. The role of the lymphocyte. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1:1996;557-568 Lippincott-Raven, Philadelphia.
24. Rekhter M., Zhang K., Narayanan A. et al. Type I collagen gene expression in human atherosclerosis: localization to specific plaque regions. Am. J. Pathol. 143:1993;1634-1648.
25. Geng Y.J., Wu Q., Muszynski M. et al. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler. Thromb. Vasc. Biol. 16:1996;19-27.
26. Boyle J.J., Bennett M.R., Proudfoot D. et al. Human monocyte/macrophages induce human vascular smooth muscle cell apoptosis in culture (abstract). J. Pathol. 184:1998;A13.
27. Davies M.J. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 82(2):1990;38-46.
28. Carvalho A.C., Colman R.W., Less R.S. Platelet function in hyperlipoproteinemia. N. Engl. J. Med. 290:1974;434-438.
29. van Willigan G., Gorter G., Akkerman J.W.N. LDLs increase the exposure of fibrinogen binding on platelets and secretion of dense granules. Arterioscler. Thromb. 14:1994;41-46.
30. Rosenen R.S., Tangney C.C. Antiatherothrombotic properties of statins. J. Am. Med. Assoc. 279:1998;1643-1650.
31. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 344:1994;1383-1389.
32. Grover S.A., Coupal L., Hu X.P. Identifying adults at increased risk of coronary heart disease: how well do the current cholesterol guidelines work? J. Am. Med. Assoc. 274:1995;801-806.
33. Sacks F.M., Pfeffer M.A., Moye L.A. et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
34. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357.
35. Downs J.R., Clearfield M., Weis S. et al. AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J. Am. Med. Assoc. 279:1998;1615-1622.
36. Prevention of coronary heart disease in clinical practice. Eur. Heart J. 19:1998;1434-1503.
37. Pitt B., Mancini G.B.J., Ellis S.G. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26:1995;1133-1139.
38. Jukema J.W., Bruschke A., van Boven A.J. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540.
39. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 344:1994;633-638.
40. Ambrose J.A., Tannenbaum M.A., Alexopoulos D. et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12:1988;56-62.
41. Little W.C., Constantinescu M., Applegate R.J. et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease. Circulation. 78:1988;1157-1166.
42. Nobuyoshi M., Tanaka M., Nosaka H. et al. Progression of coronary atherosclerosis: is coronary spasm related to progression? J. Am. Coll. Cardiol. 18:1991;904-910.
43. Giroud D., Li J.M., Urban P. et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am. J. Cardiol. 69:1992;729-732.
44. Ridker P.M., Cushman M., Stampfer M.J. et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336:1997;973-979.
45. Sweetnam P.M., Thomas H.F., Yarnell J.W.G. et al. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur. Heart. J. 17:1996;1814-1820.
46. Bernini F., Didoni G., Bonfadini G. et al. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 104:1993;19-26.
47. Shiomi M., Ito T., Tsukada T. et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler. Thromb. Vasc. Biol. 15:1995;1938-1944.
48. Tsuda Y., Satoh K., Kitadai M. et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 122:1996;225-233.
49. Dangas G., Badimon J.J., Smith D.A. et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J. Am. Coll. Cardiol. 33:1999;1294-1304.
50. Wierzbicki A.S., Lumb P.J., Semra Y.K., Crook M.A. Effect of atorvastatin on plasma fibrinogen. Lancet. 351:1998;569-570.
51. Beigel Y., Fuchs J., Snir M. et al. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity and red blood cell morphology. J. Clin. Pharmacol. 31:1991;512-517.
52. Mayer J., Eller T., Brauer P. et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann. Hematol. 64:1992;196-201.
53. Bo M., Bonino F., Neirotti M. et al. Hemorrheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology. 42:1991;106-113.
54. Avellone G., DiGarbo V., Cordova R. et al. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipo-proteinemia. Curr. Ther. Res. Clin. Exp. 55:1994;1335-1344.
55. Danqas G, Ambrose J.A., Smith D.A. Treatment of hyperlipidemia with pravastatin improves the systemic hemostatic/fibrinolytic profile and decreases thrombus formation (abstract). Eur. Heart J. 19:1998;808.
56. Mitropoulos K.A., Armitage J.M., Collins R. et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables lipoproteins and free fatty acids. Eur. Heart. J. 18:1997;235-241.
57. Davidson M., McKenney J., Stein E. et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 79:1997;1475-1481.
58. Isaacsohn J., Setaro J.F., Nicholas C. et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am. J. Cardiol. 74:1994;735-737.
59. Bevilacqua M., Bettica P., Milani M. et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am. J. Cardiol. 79:1997;84-87.
60. Lacoste L., Lam Y.J.T. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients. J. Am. Coll. Cardiol. 27:1996;413A.
61. Danqas G., Ambrose J.A., Smith D.A. et al. Treatment of hypercholesterolemic patients with and without coronary artery disease with pravastatin decreases thrombus formation under dynamic flow conditions (abstract). Eur. Heart. J. 35:1998;236.
62. Corsini A., Raiteri M., Soma M. et al. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharm. Res. 23:1991;173-180.
63. Soma M.R., Donetti E., Parolini C. et al. HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13:1993;571-578.